SCHEMBL658771

SCHEMBL658771

COc1cc(OC)c(-c2cc(C(=O)O)on2)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 1/20 0.47
LMNA P02545 1/20 0.46
HCAR2 Q8TDS4 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 4/20 0.42
ALDH1A1 P00352 4/20 0.42
HPGD P15428 3/20 0.42
RECQL P46063 1/20 0.42
THRB P10828 1/20 0.41
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
PTPN1 P18031 2/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ALPL P05186 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2730319 0.77 SMN1; SMN2 (0.67) LMNASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL656801 0.77 GAA (0.47) HCAR2SMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL656828 0.77 ALDH1A1 (0.61) RPS6KB1LMNASMN1; SMN2MAPTALDH1A1
SCHEMBL28017455 0.75 RPS6KB1 (0.46) RPS6KB1LMNASMN1; SMN2KDM4EALDH1A1
SCHEMBL19555854 0.75 HPGD (0.56) LMNASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL2731151 0.71 MAPT (0.48) HCAR2SMN1; SMN2KDM4EMAPTTHRB
SCHEMBL26690678 0.71 MAPT (0.50) SMN1; SMN2KDM4EMAPTTHRBGAA
SCHEMBL22717199 0.71 SMN1; SMN2 (0.47) HCAR2SMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL10387678 0.70 LMNA (0.49) LMNASMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL185759 0.70 HCAR2 (0.57) LMNAHCAR2SMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421833-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2012-02-29 EP claimed
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-23 US claimed
WO-2010121963-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-10-28 WO claimed
CN-102438988-B Resorcinol derivatives as hsp90 inhibitors NERVIANO MEDICAL SCIENCES SRL 2015-06-24 CN disclosed
US-8993556-B2 Resorcinol derivatives as HSP90 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-03-31 US disclosed
EP-2421833-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2012-02-29 EP disclosed
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-23 US disclosed
WO-2010121963-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P RPS6KB1 541/4885LMNA 3734/4885HCAR2 3208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.